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Abstract
Objectives
The precise relationship between sleep and physical and mental functioning in chronic fa-
tigue syndrome (CFS) has not been examined directly, nor has the impact of daytime nap-
ping. This study aimed to examine self-reported sleep in patients with CFS and explore
whether sleep quality and daytime napping, specific patient characteristics (gender, illness
length) and levels of anxiety and depression, predicted daytime fatigue severity, levels of
daytime sleepiness and cognitive functioning, all key dimensions of the illness experience.
Methods
118 adults meeting the 1994 CDC case criteria for CFS completed a standardised sleep
diary over 14 days. Momentary functional assessments of fatigue, sleepiness, cognition
and mood were completed by patients as part of usual care. Levels of daytime functioning
and disability were quantified using symptom assessment tools, measuring fatigue (Chalder
Fatigue Scale), sleepiness (Epworth Sleepiness Scale), cognitive functioning (Trail Making
Test, Cognitive Failures Questionnaire), and mood (Hospital Anxiety and Depression
Scale).
Results
Hierarchical Regressions demonstrated that a shorter time since diagnosis, higher depres-
sion and longer wake time after sleep onset predicted 23.4% of the variance in fatigue se-
verity (p<.001). Being male, higher depression and more afternoon naps predicted 25.6%
of the variance in objective cognitive dysfunction (p<.001). Higher anxiety and depression
and morning napping predicted 32.2% of the variance in subjective cognitive dysfunction
(p<.001). When patients were classified into groups of mild and moderate sleepiness,
those with longer daytime naps, those who mainly napped in the afternoon, and those with
higher levels of anxiety, were more likely to be in the moderately sleepy group.
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Conclusions
Napping, particularly in the afternoon is associated with poorer cognitive functioning and
more daytime sleepiness in CFS. These findings have clinical implications for symptom
management strategies.
Introduction
Chronic Fatigue Syndrome (CFS) is a chronic condition characterised by intense fatigue of at
least 6 months in duration and affects both physical and cognitive functioning. It is diagnosed
by a) its duration, b) not being explained by another medical condition, and c) being associated
with other symptoms such as myalgia, sleep disturbance and concentration difficulties [1]. So
defined, CFS effects between 0.2–2.6% of the adult population and women are generally 2–3
times more affected than men [2]. Although the aetiology of CFS is largely unknown, it is likely
to be multi-factorial with neuroendocrinological, autonomic, behavioural, cognitive and social
factors interacting to provoke and/or maintain symptoms [3].
Whilst fatigue is the principal complaint, this is closely followed by sleep disturbance with
87–95% of CFS patients reporting unrefreshing sleep [4–7]. More specifically, patients tend to
report fragmented sleep and sleep onset difficulties despite feeling tired [8], and one study
found that 61% of patients reported sleep continuity complaints which were independent of
cognitive functioning, fatigue and psychological wellbeing [9]. Disrupted sleep has been shown
to cause fatigue, myalgia and poor concentration in healthy volunteers and therefore sleep dis-
ruption may be not just a consequence but also a cause of the other symptoms in patients with
CFS [10].
‘Tired’ is a general term often derived from fatigue and sleepiness, which are used inter-
changeably. They are both related to unrefreshing sleep and show affective symptoms. It should
be noted that fatigue and sleepiness are also common symptoms in patients with depression
and in patients with sleep disorders. In particular, depressed patients show high sleepiness
scores on the ESS [11] and patients with sleep disorders have markedly high scores on fatigue
[12]. However, these two independent daytime symptoms remain poorly understood and are
often blurred. Despite this, a clinical distinction between fatigue and sleepiness has been shown
in patients with CFS and with a sleep disorder [13] but the distinction between these two phe-
nomena remains difficult for both patients and clinicians. Given these symptoms have different
implications in terms of diagnosis and treatment, there is an increased the risk for under diag-
nosed sleep disorders in fatigue patients [14, 15].
Daytime sleep, or napping, has been shown to have a negative impact on nocturnal sleep in
non CFS populations. For example a long nap or a nap taken later in the day or early evening
has been shown to have a detrimental effect on the length and quality of sleep during the subse-
quent night, by decreasing homeostatic pressure [16–19].
Disrupted sleep may serve to complicate the course of CFS by worsening existing symptoms.
Even if sleep complaints are common in CFS, existing studies of self-rated sleep and its associa-
tion with daytime functioning and disability are limited. Findings show sleep complaints are
associated with greater global disability and that sleep continuity complaints become worse
when the underlying condition and fatigue worsen [20]. Further, identifying sleep disturbances
to form a key dimension of CFS (alongside others such as social functioning, psychological
wellbeing and functional impairment) [9], also that CFS patients report more naps and restless
legs than healthy controls [20]. However, studies have not directly examined self-reported
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sleep and its impact on daytime physical and mental functioning in CFS, nor have they looked
at the impact of daytime napping in this population. Importantly the methodological limita-
tions (i.e. taking measures of sleep disturbance based on self-rated presence or absence of sleep
problems [20], not defining the duration of sleep complaints [9], having a limited range of
complaints [9, 21] or examining sleep related complaints lasting only one night [21]) are prob-
lematic and do not meet the standard for sleep assessment (14-day consecutive sleep diaries) to
afford appropriate characterisation of patient’s sleep patterns. It is also reasonable to consider
psychological factors as potential contributors to daytime functioning in CFS, given the well-
established relationship between anxiety, depression and fatigue [22]. Likewise, consideration
of illness length and gender is important in CFS research, given the variable nature of the dis-
ease and a condition that primarily affects women [23]. The present study therefore aims to ex-
amine self-reported sleep in men and women with CFS, and to establish whether disrupted
sleep continuity and daytime napping predict markers of daytime functioning, specifically fa-
tigue severity, sleepiness and cognitive dysfunction. The present study also aims to investigate
potential associations between illness length, anxiety, depression and daytime functioning.
Methods
Ethics Statement
The study was approved by the Newcastle and North Tyneside Local Research Ethics Commit-
tee and all subjects provided written informed consent.
Subjects
Based on a similar study [24], a power calculation (significance level of 0.05 and statistical
power of 80%) was performed to estimate participant numbers for this study. In order to detect
the smallest change of clinical relevance, a sample size of 87 subjects was required. One hun-
dred and eighteen adults (allowing for a 10% drop out rate) were recruited from a specialist
CFS service and met the 1994 CDC diagnostic criteria for CFS [1]. Participants had been
screened by a specialist physician for any medical and mental illness which could explain their
fatigue, as per the UK NICE (British National Institute for Health and Clinical Excellence)
Guidelines for CFS [25]. Participants had completed sleep diaries and functional assessments
of fatigue, sleepiness, cognition and mood as part of their usual care for CFS.
Assessment
Subjective sleep assessment. Subjective sleep was assessed using a 14-day sleep diary. The
diary was based on a sleep diary that has been used previously and demonstrated validity for
research use in CFS populations, allowing participants to monitor their sleep experience on a
daily basis [24]. Patients were required to complete the diary on waking each morning. Patients
recorded the times at which they retired to bed, identified time of lights out, the number of noc-
turnal awakenings, time of morning awakening, the number, duration and timing of daytime
naps, alcohol and caffeine consumption, and medication use. Patients returned the completed
diaries and data were averaged across the number of days completed (Mean completion 14 ± 0
days). The following sleep continuity variables were calculated; Time in Bed (TIB), Total Sleep
Time (TST), Sleep Onset Latency (SOL), Wake After Sleep Onset (WASO), Number of Awa-
kenings (NWAK), and Sleep Efficiency (SE). To characterise patient’s napping behaviour, an
overall duration of daytime napping was calculated in minutes, including duration of napping
that occurred in the morning (AM napping) and afternoon-evening (PM napping) period, on
average across the 14 days. (Descriptions of sleep variables are detailed in table 1).
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Functional and symptom assessment tools. Daytime functional assessments were complet-
ed by patients as part of their usual care. Levels of daytime sleepiness were determined by the
Epworth Sleepiness Scale (ESS). Patients self-report their chance of dozing or sleeping based
on 8 given situations. The responses are made on a Likert-type scale ranging from 0 (would
never doze/sleep) to 3 (high chance of dozing/sleeping) Total possible scores derived from the 8
questions range from 0–24, with a score of 10 or more being indicative of significant daytime
sleepiness [26].
The 11-item Chalder Fatigue Questionnaire (CFQ) evaluated fatigue severity. It is one of the
most widely used measures for assessing physical and mental symptomatic fatigue experienced
by CFS/ME patients. Four response options are available, ranging from ‘‘less than usual’’ to
‘‘much more than usual’ The Likert system for scoring was used (0, 1, 2, 3), with a total possible
score ranging from 0–33. A higher score indicates more fatigue. The test has been shown by its
authors to have good reliability (r =.86 for physical fatigue, and r =.85 for mental fatigue) and
has high internal consistency as measured by Cronbach’s alpha (.89) [27].
The Trail Making Test (TMT) was used to assess the cognitive domain of executive
functioning and speed of information processing. The task requires participants to connect-
the-dots between 25 consecutive targets on a sheet of paper. In version A of the test all of the
targets are numbers. In version B, targets alternate between numbers and letters (1, A, 2, B).
The time it takes to complete the task is the measure of performance, with longer time indicat-
ing poorer cognitive performance [28]. The TMT has been shown to demonstrate neurocogni-
tive impairments in CFS populations, with reduced performance on speed of information
processing compared to healthy controls [29, 30]
Patients completed the 25-item Cognitive Failures Questionnaire (CFQ), a tool developed
by Broadbent [31] to assess self-reported deficits in attention, perception, memory and motor
functioning. The questionnaire measures the frequency of everyday cognitive failures or lapses
by asking participants to rate how often they make mistakes on a 5-point Likert scale, from 0
(never) to 4 (very often). The instrument produces a global “cognitive complaints” score (rang-
ing from 0–100), with higher scores indicating more cognitive failures. When compared with
healthy controls, individuals with CFS have shown higher levels of global “cognitive com-
plaints” on the CFQ [32–34].
To control for the impact of anxiety and depression on daytime functioning, patients com-
pleted the 14-item Hospital Anxiety and Depression Scale (HADS). Items were rated on a
four-point Likert scale (0–3); seven items provide a measure of anxiety and seven a measure of
depression, with scores ranging from 0–21 on each subscale [35]. For both Anxiety and
Table 1. Description of sleep variables.
Abbreviated
Variable
Sleep Variable
(measure)
Description
TST Total Sleep Time
(minutes)
Amount of time asleep
SOL Sleep Onset Latency
(minutes)
Length of time from lights out to ﬁrst episode of stage 2
sleep
WASO Wake After Sleep Onset
(minutes)
Number of minutes of recorded wake following ﬁrst
episode of stage 2 sleep
NWAK Number of Awakenings
(over TSP)
Number of wake bouts following ﬁrst episode of stage 2
sleep
SE Sleep Efﬁciency (%) Percentage of time spent asleep from the amount of time
spent in bed (TST/TIB*100)
Notes: REM, rapid eye movement; TSP, total sleep period; TST, total sleep time
doi:10.1371/journal.pone.0117136.t001
Daytime Napping in CFS
PLOSONE | DOI:10.1371/journal.pone.0117136 January 9, 2015 4 / 12
Depression scales, raw scores between 8 and 10 identify mild cases, 11–15 moderate cases and
16 or above, severe cases.
Statistical analysis
The data derived from the 14 days sleep diaries and momentary functional assessments of fa-
tigue, sleepiness, cognition and mood, were pooled for each patient prior to analysis. The data
were analysed with SPSS (IBM 19.0). First, descriptive statistics for CFS patients’ self-reported
sleep variables and napping were calculated. HADS variables were also compared with pub-
lished data of a reference sample [36]. Second, Multiple Regression analyses examined the ex-
tent to which self-reported sleep and napping predicted patient’s daytime physical and mental
functioning, fatigue severity and sleepiness. Step one of each model incorporated patient char-
acteristics (age, gender, length of disease), step two consisted of the mood variables of anxiety
and depression (from HADS), and step three contained the subjective sleep parameters (SE,
NWAK, WASO, SOL, napping duration), TIB and TST were not included in the models as to-
gether these variables make up SE. Daytime symptoms measured by fatigue severity (Chalder
Fatigue Scale), daytime sleepiness (ESS) and objective and subjective cognitive functioning
(Trail Making Test, Cognitive Failures Questionnaire) were included as dependent variables in
each analysis, respectively, and checks for multicollinearity were carried out. Casewise deletion
due to missing data was defined on the basis of; a) 5% or more of an overall scale missing and/
or b) less than 14 continuous days of sleep diary recorded.
Results
Of the 118 sleep diaries returned by patients, 17 had missing data, and so 101 were used in the
analysis. The final sample therefore consisted of 101 patients with an average length since diag-
nosis of 7.8 years (±7.34). The mean age of the sample was 42.05 (±12.99), range 16–68 years,
and 81.2% were female.
21 (20.8%) patients in the sample did not report any daytime napping throughout the 14-
day period. Of the 80 (79.2%) that did nap, on average napping duration was 39.55 (±55.35)
minutes. Patients spent on average 7.80 (±16.03) minutes napping in the morning period
(AM), and 31.74 (±43.94) minutes napping in the afternoon-evening period (PM). (The mean
values for all sleep and functioning variables of the study, including demographic characteris-
tics are shown in Table 2).
The sleep diary data show patients had on average TST of 426.69 (±80.30) minutes, SOL of
37.60 (±41.67) minutes, WASO of 50.81 (±43.75) minutes and sleep efficiency at 75.74
(±13.64)%, demonstrating values in the abnormal range [37].
Fatigue severity
For fatigue severity (based on Chalder Fatigue Questionnaire scores), three predictors (length
of disease, depression, WASO) accounted for 24% of the variance. Examination of the beta
weights in the third model showed that length of disease significantly predicted Chalder Fa-
tigue scores, with people who had been diagnosed for less time being more fatigued. Depression
scores and WASO were the other significant factors (see Table 3).
Daytime sleepiness
Anxiety was the single determinant of daytime sleepiness and explained 14% of the variance in
scores on the Epworth Sleepiness Scale. Higher anxiety significantly predicted higher scores on
the ESS, based on the third model (see Table 3).
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Cognitive functioning
With regards to subjective cognitive functioning, three predictors (gender, anxiety and depres-
sion) explained 30% of the variance in scores on the Cognitive Failures Questionnaire (CFQ).
Examination of the beta weights in the third model showed that gender significantly predicted
subjective cognitive dysfunction, with women reporting more cognitive failures than men.
Higher scores on anxiety and depression were also significant predictors (see table 3).
Patients’ Trail Making Test performance (objective cognitive functioning) was within the
normal range for both TMT part A (mean = 43.79 ± 30.02 seconds) and part B (mean 92.83 ±
49.85 seconds) (completion time>78 seconds (TMT A) and> 273 seconds (TMT B) are indic-
ative of cognitive impairment [20]). For the regression, Total Trail time was used. Two predic-
tors (depression scores and napping duration) explained 14% of the variance on TMT
performance, based on the third model that incorporated the self-reported sleep variables. Ex-
amination of the beta weights in the third model showed that having a higher depression score
and a longer duration of overall daytime napping significantly predicted poorer TMT perfor-
mance (longer completion time on the test) (see Table 3).
To explore the specific time of day at which napping occurred and determine whether this
made a difference to performance on the TMT task, a further Multiple Regression analysis was
carried out. Step three of the model which incorporated the subjective sleep parameters was
modified to include total AM (morning) napping duration and total PM (afternoon-evening)
napping duration, in place of total napping duration. Three predictors (depression scores, AM
Table 2. Self-reported sleep, functional & symptom assessment data for CFS patients.
N Mean (SD)
Patient Characteristics
Gender M, F [N (%)] 101 M: 19 (19%), F: 82 (81%)
Age 101 42.05 (12.99)
Length of Illness [Months] 101 93.69 (88.12)
Sleep Continuity Parameters
Sleep Onset Latency (SOL) [Minutes] 101 37.60 (41.67)
Time In Bed (TIB) Sleep Period [Minutes] 101 569.50 (83.18)
Total Sleep Time (TST) Sleep Period [Minutes] 101 426.69 (80.30)
Number of Awakenings (NWAK) 101 1.48 (1.14)
Wake After Sleep Onset (WASO)[Minutes] 101 50.81 (43.75)
Sleep Efﬁciency (%) 101 75.74 (13.64)
Daytime Sleep (napping)
Total Napping Duration [Minutes] 80 39.55 (55.35)
Duration AM Napping [Minutes] 80 7.80 (16.03)
Duration PM Napping [Minutes] 80 31.74 (43.94)
Functional and Symptom Measures
HADS Anxiety 101 8.31 (4.62)
HADS Depression 101 8.42 (4.10)
Chalder Fatigue Questionnaire 101 25.19 (6.31)
Epworth Sleepiness Scale 101 9.87 (5.07)
TRAIL Making Test [Minutes] 96 135.31 (74.03)
Cognitive Failures Questionnaire 89 58.45 (21.14)
Notes: N differs on different measures. Data presented as means and standard deviations (SD). HADS,
hospital anxiety and depression scale
doi:10.1371/journal.pone.0117136.t002
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Table 3. Hierarchical regressions for the dependent variables; Chalder Fatigue Scale, Cognitive
Failures Questionnaire, Trail Making Task and Epworth Sleepiness Scale.
Dependent Variable
Chalder Fatigue
Scale (N = 101)
Epworth
Sleepiness
Scale (N = 101)
Cognitive
Failures
Questionnaire
(N = 89)
Trail Making
Task (N = 96)
Variables in the model β t β t β t β t
Step 1
Constant 10.11 3.54 5.07 5.03
Length of Disease -0.41** -3.27 0.00 0.01 0.13 1.17 -0.03 -0.28
Age 0.23* 2.22 0.15 1.36 0.08 0.75 0.11 0.99
Gender -0.09 -0.96 0.03 0.33 0.09 0.82 -0.24* -2.36
Adj. R2 0.08 -0.01 0.00 0.03
F 4.05** 0.75 1.05 2.12
Step 2
Constant 8.04 1.68 2.90 3.32
Length of Disease -0.31** -3.20 0.00 0.03 0.12 1.30 -0.01 -0.05
Age 0.11 1.06 0.10 0.93 -0.08 -0.84 0.01 0.10
Gender -0.00 -0.04 0.09 0.89 0.24* 2.48 -0.17 -1.67
Anxiety -0.02 -0.17 0.27* 2.41 0.33** 3.10 0.04 0.31
Depression 0.42*** 3.77 0.11 2.41 0.34** 3.02 0.33** 2.70
Adj. R2 0.22 0.09 0.96 0.30 0.13
F 6.61*** 3.05* 8.41*** 3.73**
Step 3
Constant 3.38 -0.79 2.40 2.24
Length of Disease -0.41*** -3.94 0.07 0.59 0.10 0.96 -0.02 -0.20
Age 0.07 0.62 0.11 1.03 -0.12 -1.17 -0.03 -0.31
Gender -0.01 -0.09 0.11 1.16 0.23* 2.37 -0.16 -1.64
Anxiety -0.08 -0.68 0.29* 2.48 0.32** 2.86 -0.02 -0.20
Depression 0.45*** 4.02 0.12 1.04 0.30* 2.55 0.35** 2.81
SE (%) 0.05 0.39 0.20 1.66 -0.17 -1.43 -0.10 -0.80
NWAK -0.18 -1.52 0.07 0.54 0.11 0.88 -0.11 -0.85
WASO (min) 0.34** 2.47 -0.09 -0.58 -0.02 -0.11 0.01 0.08
SOL (min) -0.03 -0.28 0.02 0.18 0.01 0.08 -0.05 -0.46
Total Napping (min) -0.05 -0.55 0.17 1.76 0.06 0.62 0.22* 2.19
Adj. R2 0.24 0.14 0.30 0.14
F 4.10*** 2.57** 4.76*** 2.49*
Notes:
*p < .05,
** p < .01,
*** p < .001;
Entries represent standardized beta coefﬁcients.
SE, sleep efﬁciency; NWAK, number of awakenings; WASO, wake after sleep onset; SOL, sleep
onset latency
doi:10.1371/journal.pone.0117136.t003
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napping duration and PM napping duration) explained 19% of the variance in time taken to
complete the TMT. Examination of the beta weights in this revised third model indicated that
having a higher depression score, a longer duration of afternoon napping (β = .49) and less
morning napping (β = -.30) were determinates of poorer objective cognitive functioning
(see table 4).
Table 4. Hierarchical regression for the dependent variable; Trail Making Task (replacing total
napping duration with AM and PM napping duration in the model).
Trail Making Task
Variables in the model β t
Step 1
Constant 5.03
Length of Disease -0.03 -0.28
Age 0.11 0.99
Gender -0.24* -2.36
Adj. R2 0.03
F 2.12
Step 2
Constant 3.32
Length of Disease -0.01 -0.05
Age 0.01 0.10
Gender -0.17 -1.67
Anxiety 0.04 0.31
Depression 0.33** 2.70
Adj. R2 0.13
F 3.73**
Step 3
Constant 2.30
Length of Disease -0.02 -0.17
Age -0.06 -0.54
Gender -0.14 -1.39
Anxiety 0.00 0.03
Depression 0.29* 2.36
SE (%) -0.11 -0.89
NWAK -0.13 -1.01
WASO (min) 0.13 0.81
SOL (min) -0.07 -0.63
Napping AM (min) -0.30* -2.15
Napping PM (min) 0.49** 3.41
Adj. R2 0.19
F 3.03**
Notes: N = 96
* p < .05,
** p < .01,
*** p < .001;
Entries represent standardized beta coefﬁcients
SE, sleep efﬁciency; NWAK, number of awakenings; WASO, wake after sleep onset; SOL, sleep
onset latency
doi:10.1371/journal.pone.0117136.t004
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Discussion
This study sought to characterize the sleep and daytime napping of patients presenting with
CFS and the extent to which their self-reported sleep and napping behaviour impacted upon
the daytime symptoms. The major findings of this study are: (i) CFS patient’s self-reported
WASO, SOL and Sleep Efficiency are in the abnormal range, but also highly variable, (ii) higher
self-reported depression, more WASO and a shorter time since diagnosis together explained
24% of patient variance in fatigue severity on the Chalder Fatigue Scale, (iii) scoring more high-
ly on depression and longer duration of PM napping, with shorter amounts of AM napping ex-
plained 14% of variance on objectively assessed cognitive functioning (TMT). Being female
and scoring more highly on anxiety and depression predicted 30% of the variance in self-
reported daily cognitive failures (CFQ); (iv) Patients with higher scores of self-rated sleepiness
(ESS) were characterised by those who self-reported higher levels of anxiety on the HADS, ex-
plaining 14% of the variance on the ESS.
The role of sleep in daytime functioning
Recent work [38] would suggest that there are distinct, objectively verifiable, sleep phenotypes
in the CFS population, and the variability in the present population may be reflecting this for
subjective variables also. For instance, the mean sleep onset latency was 37.6 minutes but the
standard deviation was 41.67 minutes. As such, whilst the present results are suggestive of the
role of disturbed sleep in the CFS population as a whole, future work should be mindful that
the nature of CFS patients’ sleep problems may differ but may fit the characteristics for a sleep-
specific phenotype.
Given this caveat, sleep still emerges as a significant predictor of impaired daytime function-
ing. Disturbed sleep at night, specifically longer amounts of wake time during the sleep period, is
significantly associated with daytime fatigue, and longer duration of napping during the after-
noon-evening period is associated with objective measures of daytime cognitive impairment.
This would suggest that rather than being “primary symptoms” of CFS, daytime fatigue and cog-
nitive dysfunction may in part be mediated by disturbed sleep and daytime napping. This in turn
would suggest that interventions, such as the sleep management strategies that form part of cog-
nitive behavioural therapy for CFS, may impact on these symptoms by way of improving sleep.
Daytime napping is a common target of CFS management interventions. In particular, Cognitive
Behavioural Therapy for Insomnia (CBT-I) discourages napping during the course of treatment;
excessive napping and extended time in bed are considered factors that can amplify existing dis-
turbances in night-time sleep by weakening the homeostatic sleep drive [39]. The present study
would add that daytime napping impairs cognitive function and may lead to a vicious circle
where such napping causes daytime sleepiness which in turn leads to daytime napping.
The role of other factors
Overall this study suggests that sleep is only one of the factors associated with daytime func-
tioning in CFS as WASO was the only sleep parameter to influence fatigue. The other key pre-
dictors were scoring higher on the depression scale of the HADS and having a more recent
diagnosis. The latter is interesting in that it would suggest that there is an “acute” phase to CFS,
whereby fatigue is higher. This would fit with the qualitative study described in the previous
chapter, and reports of patients in clinic, who frequently mention having learned to adjust to
the disease and to pace themselves the longer they have it. This has particular implications for
early stage treatment strategies, which should be involve helping people adjust to and manage
their condition. The depression finding is less easy to interpret. Patients are rightly wary of
being diagnosed as depressed and the overall means of this group are at the very low end of
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caseness. Overall the most parsimonious interpretation of these results would be that fatigue is
influenced by multiple factors, and that this study has highlighted that sleep, adjustment to ill-
ness, and mood may be pieces in the complex biopsychosocial fatigue jigsaw. Again this would
also suggest that helping people to adjust and adapt to illness, sleep management strategies,
and mood management may impact positively on daytime fatigue.
Scores on the depression scale, and scores on the anxiety scale, also emerged, along with
daytime napping, as significant contributors to objective and subjective measures of cognitive
functioning. Anxiety also emerged as a single predictor of levels of daytime sleepiness. Any ex-
planation of this is speculative, but it could be that higher anxiety, marked by higher autonomic
arousal, may produce more sleepiness.
Overall these results suggest the determinates of daytime fatigue severity, sleepiness and
cognitive functioning in CFS are multi-factorial. Whilst sleep is an important determinant, par-
ticularly disturbed sleep and daytime napping, other factors are also important. As such, any
intervention probably needs to consider each factor on an individual basis. Whilst one person
may benefit from straight forward sleep management, another person relatively early post-
diagnosis may also need help adjusting to the illness, whilst others still may need help with the
emotional impact of being ill. As there is no one sleep phenotype, there is no one typical CFS
patient. It is therefore recommended that at the minimum patients receive an individualised
sleep assessment by an experienced clinician and a sleep and napping diary.
There are several limitations to this study. Given that it is not standard procedure for pa-
tients presenting with fatigue in primary care to undergo routine sleep tests in a laboratory,
they are at increased risk of having an undiagnosed sleep disorder and potentially being misdi-
agnosed and incorrectly treated. Given the occurrence of sleepiness and sleep disturbances in
this sample, further sleep investigation is warranted, to exclude potentially undiagnosed sleep
disorders such as PLMS and Apnea, which if treated, may also alleviate fatigue. The main
methodological problems were that we largely relied on self-report data. Further, the time of
day at which functional measures are taken should be considered for future studies, particularly
where daytime napping occurs, as sleep inertia following a nap may have implications for cog-
nitive performance [40]. As for objective measures, there was no clinical screening, by way of
standardised interview for sleep disorders, no multiple sleep latency testing (MSLT) to objec-
tively measure daytime sleepiness, and no polysomnography (PSG) to objectively measure
sleep parameters. Nevertheless, subjective reports are a good way to identify the parameters of
interest for future studies, and they are also what are routinely used in the clinic with CFS pa-
tients to assess treatment outcomes. Future work should consider a triangulation of subjective
and objective reports of sleep, fatigue, sleepiness, and daytime functioning, both in the lab and
in intervention studies. In terms of the latter, the present works suggests that sleep interven-
tions merit further study in this population.
In conclusion, disturbances in sleep continuity may serve as a mediator of daytime mental
and physical dysfunction in CFS. Whilst they need to be considered in the context of other fac-
tors, it would seem that targeting disturbed sleep and napping may improve daytime fatigue
and cognitive functioning. Most current interventions in CFS are multi-factorial, and so in-
volve sleep management strategies. However to date there has been no trial of sleep interven-
tions on their own. The present study would suggest that this is an avenue worth exploring.
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